Paper Details
- Home
- Paper Details
Discovery of the Human Immunodeficiency Virus Type 1 (HIV-1) Attachment Inhibitor Temsavir and Its Phosphonooxymethyl Prodrug Fostemsavir.
Author: ColonnoRichard J, GongYi-Fei, HoHsu-Tso, KadowJohn F, LangleyDavid R, LinPin-Fang, MatiskellaJohn, MeanwellNicholas A, ParkerDawn D, PearceBradley C, UedaYasu, WangTao, YamanakaGregory A, YangZheng, YinZhiwei, ZhangZhongxing, ZhengMing
Original Abstract of the Article :
The optimization of the 4-methoxy-6-azaindole series of HIV-1 attachment inhibitors (AIs) that originated with 1 to deliver temsavir (3, BMS-626529) is described. The most beneficial increases in potency and pharmacokinetic (PK) properties were attained by incorporating N-linked, sp<sup>2</sup>-hybr...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元:
https://doi.org/10.1021/acs.jmedchem.8b00759
データ提供:米国国立医学図書館(NLM)
Temsavir: A New Hope for HIV-1 Infection
The fight against HIV-1 continues to evolve, and researchers are constantly searching for new and better therapies to combat this formidable virus. This study, published in 2018, focuses on the discovery and development of a novel drug called temsavir (BMS-626529) for treating HIV-1 infection. Temsavir belongs to a class of drugs called attachment inhibitors, meaning it prevents the virus from attaching to host cells, much like a well-placed sand dune halting the flow of a desert wind. The researchers meticulously optimized the structure of temsavir, ultimately achieving a compound that demonstrates potent antiviral activity while exhibiting favorable pharmacokinetic properties. This meticulous process is like carving a delicate sculpture out of a desert rock, requiring precision and perseverance.
Unlocking the Power of Prodrugs
Temsavir, however, faced a hurdle related to its physical properties, which limited its absorption in the body. This is where the researchers cleverly devised a solution—a prodrug called fostemsavir (BMS-663068). Prodrugs are like cleverly disguised camels that can traverse difficult terrain, delivering the payload of the drug to its intended destination. Fostemsavir, a phosphonooxymethyl prodrug of temsavir, addressed this issue by improving absorption and effectively delivering temsavir to its target. This innovative approach showcases the ingenuity of scientists in overcoming challenges and finding new solutions.
A New Frontier in HIV-1 Treatment
Fostemsavir, in its extended-release formulation, is currently undergoing phase III clinical trials. Early results are promising, indicating its potential to provide a valuable treatment option for patients with highly treatment-experienced HIV-1 infection. This breakthrough could significantly impact the lives of individuals living with HIV-1, offering them a new avenue to manage their condition. This is truly a testament to the tireless efforts of scientists in pushing the boundaries of medicine and improving the lives of others.
Dr.Camel's Conclusion
Temsavir and its prodrug fostemsavir represent a significant advance in the fight against HIV-1. The innovative approach of using a prodrug to overcome the limitations of temsavir demonstrates the ingenuity of scientists and their unwavering commitment to finding new solutions. As we continue to explore the vast desert of medical research, these groundbreaking discoveries offer a glimmer of hope for those living with HIV-1.
Date :
- Date Completed 2019-06-24
- Date Revised 2019-06-24
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.